Today’s treatments fail to address the heterogeneity of autoimmune and inflammatory diseases that affect an estimated 7% of the U.S. population. For many of these chronic, progressive diseases, the majority of patients do not respond to current treatments and many experience challenging side effects.
Rheos Medicines is developing novel, small molecule medicines to treat autoimmune and inflammatory diseases by targeting the metabolic hubs of the immune system. We are addressing the pathways essential to metabolic regulation of multiple immune cell subtypes to drive system-wide transitions in immunologic function. Using our proprietary MetPM™platform, the Rheos team integrates vast datasets and multi-omics analyses of human immune cells, enabling a new understanding of immunometabolism to identify therapeutic targets and establish molecular signatures to predict patient response.
Rheos is taking a major step forward as we focus on treating autoimmune and inflammatory diseases with greater precision.